DWP-212525

N/A

Report date: 2024/12/17 20:00:06
NME

Base Information

Drug NameDWP-212525
Drug Alias NameDWP-212525
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase BTKTyrosine-protein kinase JAK3
Therapy Area/IndicationsAutoimmune DiseasesPemphigusLupus Erythematosus, Systemic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDaewoong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaewoong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesPemphigusLupus Erythematosus, Systemic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A